Table 2 Biologics combined 3-, 6-, and 12-month outcome data (ACR20/ACR50/ACR70), adjusted for control event rate
From: Applying science in practice: the optimization of biological therapy in rheumatoid arthritis
Combined 3-, 6-, and 12-month outcome data: relative risk (95% confidence interval) versus placebo | |
|---|---|
ACR20 | |
Abatacept | 1.72 (1.38 to 2.15) |
Adalimumab | 2.08 (1.71 to 2.52) |
Etanercept | 2.09 (1.58 to 2.77) |
Infliximab | 1.71 (1.23 to 2.38) |
Rituximab | 1.93 (1.40 to 2.56) |
ACR50 | |
Abatacept | 2.29 (1.62 to 3.24) |
Adalimumab | 3.05 (2.29 to 4.07) |
Etanercept | 2.93 (1.94 to 4.44) |
Infliximab | 2.16 (1.36 to 3.41) |
Rituximab | 2.92 (1.76 to 4.83) |
ACR70 | |
Abatacept | 3.40 (2.10 to 4.94) |
Adalimumab | 4.01 (2.71 to 5.92) |
Etanercept | 3.02 (1.94 to 4.70) |
Infliximab | 2.49 (1.47 to 4.24) |
Rituximab | 4.48 (2.12 to 9.45) |